Defining a Novel Therapeutic Application of Lactoferrin for Intestinal Inflammation
Abstract
Acute intestinal infections can be inciting events for the development of chronic intestinal inflammation, such as occurs in inflammatory bowel diseases (IBD) in susceptible patients. 3.1 million people in the United States suffer from IBD, predominantly Crohn's disease (CD) and ulcerative colitis (UC). The military is not spared from this illness. The peak incidence of IBD occurs between 18-40 years of age and 2/3 of active military personnel are within this age group. IBD is of concern to the military due to the disability it causes and its high costs in terms of lost work hours, chronic health care requirements, and diminished troop readiness. In addition, IBD is on the rise in the military, increasing 2-3 fold over the past 2 decades. Among veteran populations, IBD represents one of the highest hospitalization rates and IBD-associated colorectal cancer is on the rise in this population. These data define an urgent need for identifying novel, inexpensive therapies to treat this disease.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2022
- Accession Number
- AD1190546
Entities
People
- Daniel Frank
- Edwin F. De Zoeten
Organizations
- University of Colorado Boulder